Free hepatitis B vs hepatitis C differences Topical Map Generator

Screening should target people born in high-prevalence countries, people who inject drugs, those with HIV, people with abnormal liver tests, household or sexual contacts of infected persons, and all adults at least once for HCV; repeat or targeted screening is recommended for ongoing risk exposures. Local guidelines may add age-based cohorts (eg, birth‑cohort screening) and pregnant people for HBV.

Start with a sensitive HCV antibody test; if positive, reflex to an HCV RNA test to confirm active infection. Where RNA testing is unavailable, antigen testing or point‑of‑care RNA can be used for confirmation and to rapidly link patients to treatment.

All infants should receive a birth dose of hepatitis B vaccine within 24 hours followed by the complete infant series; unvaccinated children and adults at risk (healthcare workers, people with multiple sexual partners, PWID, household contacts of infected people) should receive the vaccine. Completing the full series or documented serologic immunity is required for protection; accelerated schedules exist for rapid protection in high‑risk settings.

Current nucleos(t)ide antivirals (eg, tenofovir, entecavir) effectively suppress HBV replication and prevent liver disease progression but rarely eradicate covalently closed circular DNA; most treated patients require long‑term or lifelong therapy unless they achieve rare functional cure (HBsAg loss). Treatment decisions are based on viral load, ALT, fibrosis stage, and clinical factors including pregnancy and immunosuppression.

DAA regimens achieve sustained virologic response (virologic cure) in >95% of people with uncomplicated HCV across genotypes with 8–12 week courses; most patients including those with HIV or compensated cirrhosis can be treated. Treatment is now simplified in many guidelines to support decentralised, primary‑care delivery and test‑and‑treat models.

For pregnant people with high HBV DNA (eg, >200,000 IU/mL), antiviral therapy (typically tenofovir) started in the third trimester reduces mother‑to‑child transmission when combined with infant birth‑dose vaccine and HBIG where available. Decisions should balance viral load, safety data, and local perinatal protocols, with postpartum follow‑up for maternal therapy continuation.

People cured of HCV still need post‑SVR assessment of fibrosis; those with advanced fibrosis (F3–F4) require lifelong HCC surveillance with ultrasound ± AFP every 6 months, while those without fibrosis may need only routine clinical follow‑up and risk‑based reinfection screening. Continued harm‑reduction services and vaccination for hepatitis A and B are advised.

Use same‑day diagnosis (point‑of‑care antibody + reflex RNA/antigen or rapid RNA), nurse‑led treatment initiation, simplified protocols, mobile outreach, and strong referral pathways to minimize loss to follow‑up. Task‑shifting, community health worker engagement, and integration with HIV or maternal health services improve linkage and retention.

Breastfeeding is safe for mothers with hepatitis B or C if the infant has received hepatitis B vaccination and, where recommended, HBIG; maternal antiviral therapy is not a contraindication to breastfeeding. Routine testing of breastmilk is not indicated; counsel on avoiding nipple trauma and treat maternal mastitis promptly.

Yes—DAA cure clears the virus but does not confer immunity; people with ongoing exposure risks (eg, people who inject drugs or engage in high‑risk sex) can be reinfected and need periodic RNA screening and harm‑reduction services. Prevention strategies and repeat testing protocols should be part of post‑treatment care.